CareDx Inc. revised revenue guidance for the full year 2022. For the year, the company revising full year guidance in the range of $325 million to $335 million from $330 million to $350 million previously. This change in midpoint from $340 million to $330 million is primarily driven by revised ASP assumptions due to higher mix of commercial patients, including growth in AlloSure Lung test and shift of Medicare to Medicare Advantage patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.31 USD | +2.97% | -2.58% | -30.75% |
Apr. 16 | CareDx Appoints John Hanna as CEO, President | MT |
Apr. 16 | CareDx, Inc Appoints John W. Hanna as Chief Executive Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.75% | 418M | |
-17.60% | 11.52B | |
+39.11% | 3.27B | |
-20.67% | 2.02B | |
-29.30% | 1.44B | |
+11.45% | 1.01B | |
-6.33% | 719M | |
-51.02% | 339M | |
-2.58% | 284M | |
+25.57% | 240M |
- Stock Market
- Equities
- CDNA Stock
- News CareDx, Inc
- CareDx, Inc Revises Revenue Guidance for the Full Year 2022